|
| Tuesday, October 4, 2016 |
|
|
Launch of Uritos Tablets for Overactive Bladder in Thailand |
| Eisai Co., Ltd. and KYORIN Holdings, Inc. announced today that Eisai's Thai subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched Uritos Tablets (generic name: imidafenacin), a therapeutic agent for overactive bladder, in Thailand. more info >> |
|
|
BELVIQ XR - a New Once-daily Formulation of BELVIQ for Chronic Weight Management Now Available in the United States |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched BELVIQ XR 20mg tablets, a new once-daily formulation of BELVIQ (generic name: lorcaserin hydrochloride) for chronic weight management in the United States. more info >> |
|
| Friday, September 30, 2016 |
|
|
Eisai to Initiate Phase III Clinical Study of Anti-Cancer Agent Lenvatinib as Potential First-Line Therapy for Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced ienttoday the initiation of a global Phase III Clinical Study (Study 307, CLEAR Study) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in respective combination regimens with the anticancer agent everolimus and the anti-PD-1 antibody pembrolizumab as a potential first-line treatment for advanced renal cell carcinoma. more info >> |
|
| Thursday, September 29, 2016 |
|
|
Eisai to Present Latest Data on Lenvatinib and Eribulin at ESMO Congress 2016 |
| Eisai Co., Ltd. announced today that a series of abstracts highlighting the latest clinical and pre-clinical data on lenvatinib mesylate and eribulin mesylate will be presented during the European Society for Medical Oncology (ESMO) Congress 2016 more info >> |
|
| Wednesday, September 28, 2016 |
|
|
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Treatment of non-infectious Uveitis |
| AbbVie GK and Eisai Co., Ltd. today announced the additional approval for a new indication of HUMIRA, a fully human anti-TNF-alha monoclonal antibody formulation, in the treatment of non-infectious intermediate, posterior and panuveitis. more info >> |
|
|
Eisai Commences Provision of "EMILY" Smartphone App to Support Living with Epilepsy in Japan |
| Eisai Co., Ltd. announced today that it has commenced provision of the "EMILY" smartphone app in Japan to enable people with epilepsy and their families to enjoy greater peace of mind. more info >> |
|
|
Eisai Submits Supplemental Application for Partial Label Change for Antiepileptic Drug Fycompa |
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has submitted a supplemental application for its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel) proposing the inclusion in labelling of a description of use as monotherapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older to the U.S Food and Drug Administration (FDA) based on new FDA policy.
more info >> |
|
| Thursday, September 15, 2016 |
|
|
Eisai Receives License for New Indication for Anticancer Agent Kisplyx (Lenvatinib Mesylate) for Treatment of Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced that its European regional headquarters Eisai Europe Ltd. has received license from the European Commission for anticancer agent Kisplyx in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF) targeted therapy. more info >> |
|
| Friday, August 26, 2016 |
|
|
Anticancer Agent "Treakisym for Injection 100 mg" Approved in Japan for Additional Indication of Chronic Lymphocytic Leukemia |
| Eisai Co., Ltd. announced today that the anticancer agent TREAKISYM for Injection 100 mg (generic name: bendamustine hydrochloride, "TREAKISYM") has been approved in Japan for an additional indication of chronic lymphocytic leukemia. more info >> |
|
| Tuesday, August 23, 2016 |
|
|
Eisai to Launch Chocola BB Mouth Ulcer Repair Shot |
| Eisai Co., Ltd. announced today that it will launch "Chocola BB Mouth Ulcer Repair Shot"(Third-class OTC drug) for mouth ulcers in Japan on Thursday, August 25. more info >> |
|
|
|
